Hr-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hr-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC [Phase 2]
A Phase 2 clinical trial update reports results for sacituzumab govitecan with or without pembrolizumab in HR-positive, HER2-negative metast…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy [NA]
This completed clinical trial evaluated patient-reported outcomes and physical activity in Japanese patients with HR+/HER2- advanced breast …
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer [Phase 2]
Phase 2 study of ZW25 (zanidatamab) with palbociclib and fulvestrant in HER2+/HR+ advanced breast cancer completed; results have been posted…
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial. [Phase 2]
A Phase 2 trial evaluating dalpiciclib in combination with fulvestrant and compound gossyfol acetate tablets for women with HR-positive, HER…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer [Phase 2]
Phase 2 clinical trial updating tucidinostat in combination with nab-paclitaxel for advanced HR+/HER2- breast cancer.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating HS-10342 in Chinese patients with HR+/HER2- advanced and/or metastatic breast cancer is in the study pha…